title: Functional Characteristics of C-terminal Lysine to Cysteine Mutant Form of CTLA-4Ig.
abstract: CTLA-4Ig is regarded as an inhibitory agent of the T cell proliferation via blocking the costimulatory signal which is essential for full T cell activation. To improve applicability, we developed the CTLA-4Ig-CTKC in which the c-terminal lysine had been replaced by cysteine through single amino acid change. The single amino acid mutation of c-terminus of CTLA-4Ig was performed by PCR and was checked by in vitro transcription and translation. DNA construct of mutant form was transfected to Chinese hamster ovary (CHO) cells by electroporation. The purified proteins were confirmed by Western blot and B7-1 binding assay for their binding ability. The suppressive capacity of CTLA-4Ig-CTKC was evaluated by the mixed lymphocyte reaction (MLR) and in the allogeneic pancreatic islet transplantation model. CTLA-4Ig-CTKC maintained binding ability to B7-1 molecule and effectively inhibits T cell proliferation in MLR. In the murine allogeneic pancreatic islet transplantation, short-term treatment of CTLA-4Ig-CTKC prolonged the graft survival over 100 days. CTLA-4Ig-CTKC effectively inhibits immune response both in MLR and in allogeneic islet transplantation model, indicating that single amino acid mutation does not affect the inhibitory function of CTLA-4Ig. CTLA-4Ig-CTKC can be used in vehicle-mediated drug delivery system such as liposome conjugation.
authors.affiliation: Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 110-799, Korea. ; Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Korea. ; Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea.
authors.forename: Bongi
authors.initials: B
authors.lastname: Kim
authors.forename: Jun-Seop
authors.initials: JS
authors.lastname: Shin
authors.forename: Chung-Gyu
authors.initials: CG
authors.lastname: Park
keywords: CTLA-4Ig; Costimulation; Mutation; T cell
references.citation: Crit Rev Immunol. 1998;18(5):389-418
references.pmid: 9784967
references.citation: Transplantation. 2010 Dec 27;90(12):1528-35
references.pmid: 21076381
references.citation: Diabetes. 1967 Jan;16(1):35-9
references.pmid: 5333500
references.citation: Pharm Res. 2003 Aug;20(8):1239-48
references.pmid: 12948022
references.citation: Am J Transplant. 2010 Mar;10(3):547-57
references.pmid: 20415898
references.citation: Immunity. 1994 Aug;1(5):405-13
references.pmid: 7882171
references.citation: Immunol Today. 1994 Jul;15(7):321-31
references.pmid: 7522010
references.citation: Transplantation. 2001 Oct 27;72(8):1423-32
references.pmid: 11685115
references.citation: Am J Transplant. 2005 Mar;5(3):443-53
references.pmid: 15707398
references.citation: Annu Rev Immunol. 1983;1:143-73
references.pmid: 6443557
references.citation: Science. 1992 Aug 7;257(5071):789-92
references.pmid: 1323143
references.citation: J Immunol. 1995 Aug 1;155(3):1544-55
references.pmid: 7636216
references.citation: J Am Soc Nephrol. 2010 Sep;21(9):1587-96
references.pmid: 20634298
references.citation: N Engl J Med. 2005 Sep 15;353(11):1114-23
references.pmid: 16162882
references.citation: Annu Rev Immunol. 1996;14:233-58
references.pmid: 8717514
references.citation: Am J Transplant. 2010 Mar;10(3):535-46
references.pmid: 20415897
references.citation: Annu Rev Immunol. 2001;19:225-52
references.pmid: 11244036
references.citation: J Clin Invest. 1999 May;103(9):1243-52
references.pmid: 10225967
references.citation: Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):11102-5
references.pmid: 1332070
references.citation: Annu Rev Immunol. 2006;24:65-97
references.pmid: 16551244
references.citation: Am J Transplant. 2010 Mar;10(3):441-2
references.pmid: 20415895
references.citation: N Engl J Med. 2003 Nov 13;349(20):1907-15
references.pmid: 14614165